Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Medexus Pharmaceuticals Inc
T.MDP
Alternate Symbol(s):
MEDXF
Healthcare
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its...
lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:MDP)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Post by
nozzpack
on Aug 10, 2023 12:49pm
Price to book Valuation
Price top book includes debt and other balance sheet metrics which also makes it a valuable proxy tool. Price to book for this sector is trending around 7 times..see link below. This would place MDP
...more
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Comment by
nozzpack
on Aug 10, 2023 11:50am
RE:Very positive CC
The CD is convertible at a price of $6.30 per share some of which will be redeemed with the $20 m in cash expected to be in hand by September . This will considerably upside the balance sheet without
...more
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Comment by
nozzpack
on Aug 10, 2023 11:35am
RE:RE:Ebitda Sector Multiple
EV to Ebitda is 14.9.. https://www.statista.com/statistics/1030111/enterprise-value-to-ebitda-in-the-health-and-pharmaceuticals-sector-worldwide/#:~:text=Worldwide%2C%20the%20average%20value%20of
...more
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Post by
nozzpack
on Aug 10, 2023 11:31am
Very positive CC
.Much info, and more will be provided when the company presents at the Share Series Event this coming Monday .. Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company
...more
(2139)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Aug 10, 2023 7:40am
RE:RE:Ebitda Sector Multiple
With large o/s debt, EV/ebitda multiples are more relevant.
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Comment by
nozzpack
on Aug 10, 2023 7:25am
RE:Another Very Strong Quarter with 37% growth
What stands out in this first look at F2023/24 ( Q1 ) is the revenue growth rate of 37 %. This is statistically indifferent to the 39% growth observed in F22/23. Q1 is not the strongest quarter as
...more
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Comment by
nozzpack
on Aug 09, 2023 6:21pm
RE:Ebitda Sector Multiple
Ebitda of $6,6 million US in Q1 which is about $8.2 million in cad. Annualized, Thats about $33 million CAD Ebitda in this sector has a muktiple of 13 times ;( see my recent post ) which
...more
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Post by
nozzpack
on Aug 09, 2023 6:13pm
Another Very Strong Quarter with 37% growth
Fiscal Q1 2024 revenue reflects a 37% increase over fiscal Q1 2023, demonstrating strong revenue growth and continued overall performance Management to host conference call at 8:00 AM Eastern time
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 09, 2023 5:31pm
New Press Release - Medexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million
Fiscal Q1 2024 revenue reflects a 37% increase over fiscal Q1 2023, demonstrating strong revenue growth and continued overall performanceManagement to host conference call at 8:00 AM Eastern time on Thursday, August 10, 2023Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 9, 2023)...
read article.
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Post by
nozzpack
on Aug 05, 2023 4:57am
Exclusive Rights to Terbinafide HCL in Canada
Interestingly , it's the top treatment for toenail fungus .. https://www.verywellhealth.com/best-toenail-fungus-treatments-4174023
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Post by
nozzpack
on Aug 04, 2023 1:06pm
Ebitda Sector Multiple
Approximately 13 times for this sector.. https://firstpagesage.com/business/pharmaceutical-company-valuation-ebitda-multiples/ Trailing, MDP had $16.1 million US in Ebitda in 2022 which
...more
(229)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 04, 2023 12:00pm
Medexus to Participate in Fireside Chat at SHARE Series Even
JUST IN: $MEDXF Medexus to Participate in Fireside Chat at SHARE Series EventToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 4, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX
...more
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Post by
nozzpack
on Aug 04, 2023 11:13am
Valuation shows substantial upside
so, $31 million is about $40 million in CAD . Annualized and assuming no further growth, that's bout $160 million per year . MDP has only 20.5 m shares so its current market cap at $3 per share
...more
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Post by
nozzpack
on Aug 04, 2023 11:02am
Q1 looks strong..Promoting it the next Week
ORIGINAL: Medexus to Participate in Fireside Chat at SHARE Series Event 2023-08-04 07:00 ET - News Release Toronto, Ontario and Chicago, Illinois--(Newsfile Corp
...more
(3572)
•••
nozzpack
X
View Profile
View Bullboard History
Post by
nozzpack
on Aug 04, 2023 11:00am
Q1 next Week
Medexus to release fiscal Q1 results Aug. 9 2023-08-02 13:51 ET - News Release Mr. Ken d'Entremont reports MEDEXUS SCHEDULES FIRST FISCAL QUARTER 2024 CONFERENCE
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >